ArticleAmerican journal of translational research2025
Valproate sodium-associated acute pancreatitis: a case report and systematic analysis of antiepileptic drug adverse events in FAERS.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-induced pancreatitis (DIP) has been increasingly recognized owing to the increased use of pharmacotherapy; however, valproate sodium (VPA)-associated DIP remains uncommon, particularly in adolescents, though severe and life-threatening cases have been documented in this population. We report an adolescent patient with epilepsy who developed DIP following long-term VPA therapy and further investigate the risk of antiepileptic drug (AED)-related pancreatitis through an analysis of the FDA Adverse Event Reporting System (FAERS) database.
methodsWe present a case of an adolescent male with epilepsy who developed DIP after VPA treatment. OpenVigil 2.1 was used to conduct a pharmacovigilance analysis of all AED-related adverse events (AEs) reported to the FAERS up to June 2024. Signal detection was performed using the reporting odds ratio (ROR) and proportional reporting ratio (PRR).
resultsAmong 136,681 cases from 104 countries, 2237 (1.64%) were associated with acute pancreatitis (AP), including 918 serious cases. All evaluated AEDs - except brivaracetam - had ROR and PRR values >1, indicating a potential risk of pancreatitis. The highest-risk AEDs were amobarbital, quetiapine, VPA, and carbamazepine.
conclusionThis study reinforces the association between VPA and AP while providing a broader pharmacovigilance assessment of AED-induced pancreatitis. Clinicians should remain vigilant when prescribing AEDs, particularly to high-risk patients, given the potential of serious pancreatic toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.